Apr 13, 2024
Source:
CIIC Spring 2024 Conference, Arlington, TX
Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks
Apr 13, 2024
Source:
CIIC Spring 2024 Conference, Arlington, TX
Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Mar 16, 2024
Source:
3rd ITACA National Congress, Milan
Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Mar 16, 2024
Source:
2024 HAEi Regional Conference Americas, Panama City, Panama
Efficacy and Safety of Oral Deucrictibant, a Potent Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Mar 16, 2024
Source:
2024 HAEi Regional Conference Americas, Panama City, Panama
Understanding Patient Reasons not to Treat All Hereditary Angioedema (HAE) Attacks and Characteristics of Untreated HAE Attacks: Results from a Real World Survey
Mar 15, 2024
Source:
3rd ITACA National Congress, Milan
Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks
Mar 15, 2024
Source:
3rd ITACA National Congress, Milan
Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Mar 15, 2024
Source:
3rd ITACA National Congress, Milan
Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema
Mar 15, 2024
Source:
3rd ITACA National Congress, Milan
Need for Caregiver Support for People Living With Hereditary Angioedema in European Countries
Mar 15, 2024
Source:
2024 HAEi Regional Conference Americas, Panama City, Panama
Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design
Mar 15, 2024
Source:
2024 HAEi Regional Conference Americas, Panama City, Panama
Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Mar 15, 2024
Source:
2024 HAEi Regional Conference Americas, Panama City, Panama
Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks
Feb 23, 2024
Source:
2024 AAAAI Annual Meeting, Washington D.C.
Understanding the Reasons not to Treat All HAE Attacks and Patient Satisfaction for on-Demand Treatment (ODT). Results from the HAE Wave II Disease Specific Program™ (DSP™) 2023.
Feb 23, 2024
Source:
2024 AAAAI Annual Meeting, Washington D.C.
Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Oral Deucrictibant in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Feb 04, 2024
Source:
WSAAI Annual Meeting 2024, Koloa, Hawaii
Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks
Feb 04, 2024
Source:
WSAAI Annual Meeting 2024, Koloa, Hawaii
Efficacy and Safety of Bradykinin B2 Receptor Antagonism With Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Dec 08, 2023
Source:
GA²LEN UCARE Conference 2023, São Paulo, Brazil
Treatment of HAE Attacks with Deucrictibant: RAPIDe-1 Phase2 Trial Results
Dec 08, 2023
Source:
GA²LEN UCARE Conference 2023, São Paulo, Brazil
Analyzing Symptom Relief Definitions in HAE Using AMRA and PGI-C/PGI-S
Dec 08, 2023
Source:
GA²LEN UCARE Conference 2023, São Paulo, Brazil
Early-Onset Response to Treatment of Hereditary Angioedema Attacks with Deucrictibant
Nov 11, 2023
Source:
ACAAI 2023 Annual Scientific Meeting, Anaheim, CA
Understanding the reasons not to treat all HAE attacks and satisfaction for on-demand treatment: physician- and patient-reported data
Nov 10, 2023
Source:
ACAAI 2023 Annual Scientific Meeting, Anaheim, CA
Deucrictibant immediate-release capsule reduces time to end of progression of hereditary angioedema attacks’ manifestations
Oct 23, 2023
Source:
APAAACI 2023 International Conference, Singapore
Bradykinin B2 receptor antagonist deucrictibant immediate-release capsule for treatment of HAE attacks: Phase 2
Oct 14, 2023
Source:
CIIC Fall 2023 Conference, Dallas, TX
Efficacy and safety of bradykinin B2 receptor antagonism with deucrictibant immediate-release capsule for treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
Oct 14, 2023
Source:
CIIC Fall 2023 Conference, Dallas, TX
Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule in patients with hereditary angioedema attacks
Sep 15, 2023
Source:
18th German Allergy Congress, Bonn, Germany
Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
Sep 15, 2023
Source:
18th German Allergy Congress, Bonn, Germany
Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks
Sep 02, 2023
Source:
HAEi Regional Conference EMEA, Munich
Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
Sep 01, 2023
Source:
HAEi Regional Conference EMEA, Munich
Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks
Sep 01, 2023
Source:
HAEi Regional Conference EMEA, Munich
Efficacy and safety of bradykinin B2 receptor antagonism with oral deucrictibant in prophylaxis of hereditary angioedema attacks: CHAPTER-1 phase 2 trial design
Jul 21, 2023
Source:
U.S. HAEA National Summit, Orlando, FL
Efficacy and safety of bradykinin B2 receptor antagonism with deucrictibant immediate-release capsule for treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
Jul 21, 2023
Source:
U.S. HAEA National Summit, Orlando, FL
Treatment with oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule improves hereditary angioedema attack symptoms
Jun 11, 2023
Source:
2023 EAACI Hybrid Congress, Hamberg, Germany
Efficacy and Safety of Oral Administered Bradykinin B2 Receptor Inhibitor PHVS416 in Treatment of Hereditary Angioedema Attacks: Topline Results of RAPIDe-1 Phase 2 Trial
Jun 11, 2023
Source:
2023 EAACI Hybrid Congress, Hamberg, Germany
Treatment with Oral Administered Bradykinin B2 Receptor Inhibitor PHVS416 Improves Hereditary Angioedema Attack Symptoms
May 06, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
The EC85 Derived from the Oral Bradykinin B2 Receptor Antagonist Deucrictibant (PHA121) Against Bradykinin Effects in Healthy Volunteers Predicts the Onset and Duration of Its Clinical Effects in Hereditary Angioedema
May 06, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
Cardiovascular safety of the orally administered bradykinin B2 receptor antagonist, deucrictibant (PHA121, PHA-022121)
May 06, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate Release Capsule (PHVS416) in Treatment of Hereditary Angioedema Attacks: Topline Results of RAPIDe 1 Phase 2 Trial
May 06, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
Efficacy of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) by attack location in the RAPIDe-1 phase 2 clinical trial for treatment of hereditary angioedema attacks
May 05, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks
Mar 18, 2023
Source:
2023 HAEi Regional Conference APAC, Bangkok
Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Feb 26, 2023
Source:
2023 AAAAI Annual Meeting, San Antonio, TX
Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Nov 13, 2022
Source:
ACAAI Annual Scientific Meeting 2022, Louisville, KY
Pharmacokinetics of PHVS719, extended-release tablet formulation of PHA121, a first-in-class oral human bradykinin B2-receptor antagonist
Nov 12, 2022
Source:
ACAAI Annual Scientific Meeting 2022, Louisville, KY
Development of PHVS719: an Oral Extended-Release Bradykinin B2 Receptor Antagonist to Prevent Hereditary Angioedema Attacks
Oct 07, 2022
Source:
2022 HAEi Global Leadership Workshop, Frankfurt
Development of two novel oral formulations of a first in class bradykinin B2 receptor antagonist for on demand and prophylactic treatment of hereditary angioedema
Sep 16, 2022
Source:
Bradykinin Symposium 2022, Berlin
Development of PHA121 for On-Demand and Prophylactic Treatment of HAE
Jun 07, 2022
Source:
Satellite Symposium Kinin 2022
Tailored drug development for patients living with HAE
Mar 22, 2022
Source:
International Immunopharmacology
In vitro pharmacological profile of PHA-022121, a small molecule bradykinin B2 receptor antagonist in clinical development
Jul 10, 2021
Source:
EAACI Annual Congress 2021, Virtual
Multiple dose administration of PHA-022121, an orally available, bradykinin B2 receptor antagonist is well tolerated and shows a favorable pharmacokinetic profile for prophylactic treatment of HAE
Jun 04, 2021
Source:
12th C1-inhibitor Deficiency and Angioedema Workshop, Virtual
Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE
Feb 26, 2021
Source:
2021 AAAAI Annual Meeting, Virtual
Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE
Nov 13, 2020
Source:
ACAAI Annual Scientific Meeting 2020, Virtual
Bradykinin Challenge Provides Surrogate Endpoints For Hereditary Angioedema Treatment
Nov 13, 2020
Source:
ACAAI Annual Scientific Meeting 2020, Virtual
PHA-022121, a Selective Bradykinin-B2-Receptor Antagonist, Is Safe and Shows Rapid Oral Bioavailability in Humans
Jul 30, 2020
Source:
Frontiers in Pharmacology
In Vitro Pharmacological Profile of a New Small Molecule Bradykinin B2 Receptor Antagonist
Apr 09, 2020
Source:
2020 AAAAI Annual Meeting, Virtual
PHA-022121, a First in Class Oral Bradykinin B2 Receptor Antagonist in Clinical Development: Proof of Concept Study in a Translational Monkey Bradykinin Challenge Model